S&P 500   2,995.99 (-0.36%)
DOW   26,788.10 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
GOOGL   1,241.20 (-0.25%)
AMZN   1,765.73 (-1.12%)
CGC   21.15 (+3.93%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
S&P 500   2,995.99 (-0.36%)
DOW   26,788.10 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
GOOGL   1,241.20 (-0.25%)
AMZN   1,765.73 (-1.12%)
CGC   21.15 (+3.93%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
Log in

Actinium Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ATNM)

$0.21
-0.01 (-4.55 %)
(As of 10/22/2019 04:00 PM ET)
Today's Range
$0.20
Now: $0.21
$0.22
50-Day Range
$0.19
MA: $0.22
$0.24
52-Week Range
$0.19
Now: $0.21
$0.76
Volume216,110 shs
Average Volume964,078 shs
Market Capitalization$34.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNM
CUSIPN/A
CIKN/A
Phone646-767-3870

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees30
Market Cap$34.11 million
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.


Actinium Pharmaceuticals (NASDAQ:ATNM) Frequently Asked Questions

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the NASDAQ under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NASDAQ:ATNM) announced its quarterly earnings results on Friday, August, 9th. The company reported ($0.03) earnings per share (EPS) for the quarter. View Actinium Pharmaceuticals' Earnings History.

When is Actinium Pharmaceuticals' next earnings date?

Actinium Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Actinium Pharmaceuticals.

What is the consensus analysts' recommendation for Actinium Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.

Has Actinium Pharmaceuticals been receiving favorable news coverage?

Media headlines about ATNM stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Actinium Pharmaceuticals earned a news impact score of -1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Actinium Pharmaceuticals.

Who are some of Actinium Pharmaceuticals' key competitors?

What other stocks do shareholders of Actinium Pharmaceuticals own?

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:
  • Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
  • Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 64)
  • Mr. Anil Kapur, Chief Commercial Officer (Age 50)

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $0.21.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $34.11 million. Actinium Pharmaceuticals employs 30 workers across the globe.View Additional Information About Actinium Pharmaceuticals.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is http://www.actiniumpharma.com/.

How can I contact Actinium Pharmaceuticals?

The company can be reached via phone at 646-767-3870.


MarketBeat Community Rating for Actinium Pharmaceuticals (NASDAQ ATNM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  11 (Thanks for Voting!)
Underperform Votes:  9 (Thanks for Voting!)
Total Votes:  20
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel